Alaaeldin M K Bashier1, Azza Khalifa Bin Hussain2, Fatheya Alawadi3, Fatima Alsayyah4, Maryam Alsaeed5, Fauzia Rashid6, Elamin Abdelgadir7, Fawzi Bachet8, Sona Abuelkheir9, Mohamed Elsayed10, Mohamed Hassanein11. 1. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: aekhidir@dha.gov.ae. 2. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: aabinhussain@dha.gov.ae. 3. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: ffalawadi@dha.gov.ae. 4. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: fasayyah@dha.gov.ae. 5. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: aalsaeed@dha.gov.ae. 6. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: frashid@dha.gov.ae. 7. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: Eelaminabdelgader@dha.gov.ae. 8. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: Fbachet@dha.gov.ae. 9. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: smabuelkheir@dha.gov.ae. 10. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: maelsayed@dha.gov.ae. 11. Endocrine Department, Dubai Hospital, United Arab Emirates. Electronic address: mmhassanein@dha.gov.ae.
Abstract
AIM: We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed. METHODS: We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan. RESULTS: HbA1c reduced from 7.9 ± 1.20 pre-Ramadan to 7.7 ± 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 ± 79.8 mg/dl before Ramadan improved significantly to reach 289.3 ± 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028). CONCLUSION: People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data.
AIM: We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetespatients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed. METHODS: We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan. RESULTS: HbA1c reduced from 7.9 ± 1.20 pre-Ramadan to 7.7 ± 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 ± 79.8 mg/dl before Ramadan improved significantly to reach 289.3 ± 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028). CONCLUSION:People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data.
Authors: Dana Abdelrahim; MoezAlIslam E Faris; Mohamed Hassanein; Ayman Z Shakir; Ayesha M Yusuf; Aljohara S Almeneessier; Ahmed S BaHammam Journal: Front Endocrinol (Lausanne) Date: 2021-03-08 Impact factor: 5.555